A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+metastatic breast cancer (MBC)

被引：1
|
作者：
Jhaveri, Komal L.
Hamilton, Erika Paige
Miller, Kathy
Roche, Maria
Berger, Mark S.
Winer, Eric P.
Lin, Nancy U.
机构：
[1] NYU, Inst Canc, New York, NY USA
[2] Sarah Cannon Res Inst, Brentwood, Essex, England
[3] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[4] Kadmon Corp, Wilmington, MA USA
[5] Kadmon Corp, New York, NY USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.608
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
608
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+breast cancer (TBCRC 050).
    Stringer-Reasor, Erica Michelle
    Li, Yufeng
    Witherspoon, Felicia
    Specht, Jennifer M.
    Mesias, Jesus Del Santo Anampa
    Nanda, Rita
    Dees, Elizabeth Claire
    Wolff, Antonio C.
    Krop, Ian E.
    Lin, Nancy U.
    Rimawi, Mothaffar F.
    Yang, Eddy Shih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [12] Multicenter phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+metastatic breast cancer (MBC) who failed prior trastuzumab therapy
    Lee, S. C.
    Chen, S-C.
    Dai, M-S.
    Lee, G. E.
    Liu, C-L.
    Chan, A.
    Chang, H-K.
    Tseng, L-M.
    Chay, W. Y.
    Chow, L. W. C.
    Peneyra, J. L.
    Rau, K-M.
    Wang, H-C.
    Guancia, A. A.
    Head, M.
    Chiu, J. W. Y.
    Robinson, B.
    Lindmark, B.
    McIntyre, N.
    Hsieh, C-Y.
    ANNALS OF ONCOLOGY, 2017, 28 : 30 - 30
  • [13] Larotaxel (L) in combination with trastuzumab in patients with HER2+metastatic breast cancer (MBC): Interim analysis of an open phase II label study
    Dieras, V.
    Viens, P.
    Veyret, C.
    Romieu, G.
    Awada, A.
    Lidbrink, E.
    Bonnefoi, H.
    Mery-Mignard, D.
    Dalenc, F.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [14] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+metastatic breast cancer (MBC)
    Borges, Virginia F.
    Hamilton, Erika
    Yardley, Denise A.
    Chaves, Jorge
    Aucoin, Nathalie
    Ferrario, Cristiano
    Walker, Luke
    Krop, Ian
    CANCER RESEARCH, 2015, 75
  • [15] Efficacy results of a phase lb study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+metastatic breast cancer (MBC), including patients (pts) with brain metastases.
    Borges, Virginia F.
    Ferrario, Cristiano
    Aucoin, Nathalie
    Falkson, Carla Isadora
    Khan, Qamar J.
    Krop, Ian E.
    Welch, Stephen
    Bedard, Philippe L.
    Conlin, Alison Katherine
    Chaves, Jorge
    Walker, Luke N.
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [16] Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+metastatic breast cancer (MBC).
    De La Pena, Lorena
    Cortes, Javier
    Manikhas, Alexey
    Roman, Laslo
    Semiglazov, Vladimir
    Biakhov, Mikhail Yu
    Dasappa, Lokanatha
    Llombart, Antonio
    Rozencweig, Marcel
    Forenza, Salvatore
    Goldfarb, Ronald H.
    Matera, Jeri
    Azarnia, Nozar
    Hudis, Clifford
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [17] A single-center, open-label phase 1b study of entinostat, and lapatinib alone, and in combination with and trastuzumab in patients with HER2+metastatic breast cancer after progression on trastuzumab
    Lim, B.
    Jackson, S.
    Alvarez, R. H.
    Ibrahim, N. K.
    Willey, J. S.
    Murthy, R. K.
    Booser, D. J.
    Giordano, S. H.
    Barcenas, C. H.
    Brewster, A.
    Walters, R. S.
    Brown, P. H.
    Tripathy, D.
    Valero, V.
    Ueno, N. T.
    CANCER RESEARCH, 2016, 76
  • [18] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with adotrastuzumab emtansine (T-DM1), in HER2+metastatic breast cancer (MBC)
    Borges, Virginia F.
    Hamilton, Erika Paige
    Yardley, Denise A.
    Moulder, Stacy L.
    Hortobagyi, Gabriel N.
    Walker, Luke N.
    Krop, Ian E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [19] Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): phase 2 trial.
    Modi, S.
    Stopeck, A.
    Kinden, H.
    Sugarman, S.
    Ma, W.
    Solit, D.
    Kersey, K.
    Johnson, R.
    Hannah, A. L.
    Hudis, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S269 - S270
  • [20] The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+Metastatic Breast Cancer (TBCRC 062)
    Parsons, Heather
    Ruddy, Kathryn
    Morganti, Stefania
    Smith, Karen
    Attaya, Victoria
    Kallfelz, Eliza
    DeMeo, Michelle
    LaScala, Jamie
    Mertz, Shirley
    Pollastro, Teri
    Spears, Patricia
    Brufsky, Adam
    Dang, Chau
    Dent, Susan
    Elkhanany, Ahmed
    Gwin, WIlliam
    O'Sullivan, Ciara
    Miller, Kathy
    Nunnery, Sara
    Walsh, Elaine
    Storniolo, Anna Maria
    Tolaney, Sara
    Tayob, Nabihah
    Wolff, Antonio
    Winer, Eric
    Rimawi, Mothaffar
    Krop, Ian
    Lin, Nancy
    CANCER RESEARCH, 2024, 84 (09)
12345